Study: Childhood vaccines are safe, low risk

There are some risks associated with some childhood vaccinations, but overall the evidence shows that vaccines are very safe, according a new study. » Full article

ADA: Intravitreal aflibercept injection shows consistency of effect across levels of HbA1c control in DME

Patients with diabetic macular edema (DME) treated with aflibercept injection significantly improved vision and reduced the severity of diabetic retinopathy versus laser photocoagulation, according to data recently presented at the American Diabetes Association (ADA) Scientific Sessions in San Francisco.
» Full article

Continuing Education

MTM essentials for heart failure management

This month's article is the fifth in a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities form the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to review the stages and pharmacologic strategies relevant to medication therapy management of heart failure .

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in.

Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net. This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.

• BLOG: The goal of vaccines: It's worth a shot

• ADA: Study says non-insulin dulaglutide demonstrates effective blood glucose control in diabetes patients

RESOURCES

Latest Clinical News

[BLOG] Blessings in disguise: Should formularies welcome premium-priced bladder cancer drugs?

The management of bladder cancer represents one of the most costly and underestimated challenges in the oncology spectrum. Despite having the 6th highest incidence of any cancer in the United States, high recurrence rates and the need to constantly monitor patients act as the primary drivers for the high expenditures associated with the disease.
» Full article